PMID- 20596502
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20110714
LR  - 20220408
IS  - 1178-203X (Electronic)
IS  - 1176-6336 (Print)
IS  - 1176-6336 (Linking)
VI  - 6
DP  - 2010 Jun 24
TI  - Management of ANCA-associated vasculitis: Current trends and future prospects.
PG  - 253-64
AB  - The antineutrophil cytoplasm antibody (ANCA)-associated vasculitides are a 
      spectrum of heterogeneous autoimmune diseases characterized by necrotizing small 
      vessel vasculitis and the presence of ANCA. These chronic multisystem disorders 
      may be life-threatening if there is major organ involvement, such as acute renal 
      failure or pulmonary hemorrhage, and require significant initial 
      immunosuppression and long-term maintenance treatment. Long-established protocols 
      using cyclophosphamide and prednisolone have resulted in dramatically improved 
      outcomes for patients since the 1970s. Subsequently, international collaboration 
      has contributed to a growing evidence base and consensus in the management of 
      these rare disorders. Modifications to traditional treatment protocols by the use 
      of azathioprine or methotrexate rather than cyclophosphamide, and the 
      introduction of newer agents, such as rituximab, has maintained outcomes whilst 
      decreasing toxicity. However, the treatment limitations of incomplete efficacy, 
      infection, and cumulative toxicity persist. These issues have continued to drive 
      the search for safer and more effective modulation of the immune system using 
      targeted immunotherapy. This review will explore the current evidence base for 
      management of ANCA-associated vasculitis and future treatment prospects.
FAU - Hamour, Sally
AU  - Hamour S
AD  - Imperial College Kidney and Transplant Institute, Imperial College, London, UK.
FAU - Salama, Alan D
AU  - Salama AD
FAU - Pusey, Charles D
AU  - Pusey CD
LA  - eng
PT  - Journal Article
DEP - 20100624
PL  - New Zealand
TA  - Ther Clin Risk Manag
JT  - Therapeutics and clinical risk management
JID - 101253281
PMC - PMC2893757
OTO - NOTNLM
OT  - ANCA
OT  - treatment
OT  - vasculitis
EDAT- 2010/07/03 06:00
MHDA- 2010/07/03 06:01
PMCR- 2010/06/24
CRDT- 2010/07/03 06:00
PHST- 2010/06/10 00:00 [received]
PHST- 2010/07/03 06:00 [entrez]
PHST- 2010/07/03 06:00 [pubmed]
PHST- 2010/07/03 06:01 [medline]
PHST- 2010/06/24 00:00 [pmc-release]
AID - tcrm-6-253 [pii]
AID - 10.2147/tcrm.s6112 [doi]
PST - epublish
SO  - Ther Clin Risk Manag. 2010 Jun 24;6:253-64. doi: 10.2147/tcrm.s6112.